
-
Iran, US hold new round of high-stakes nuclear talks
-
Up at dawn for front-row seat to history at Francis's funeral
-
Pakistan ready to 'defend sovereignty' after India threats
-
Huge crowds flock to Vatican for Pope Francis's funeral
-
Xi says China must 'overcome' AI chip challenges
-
Indian army says new exchange of gunfire with Pakistan
-
Epstein accuser Virginia Giuffre takes own life in Australia: family
-
Hundreds of buildings damaged, dozens injured in 6.3 Ecuador quake
-
India and Pakistan's Kashmir fallout hits economy too
-
Francis's funeral to be grand farewell to 'pope of the poor'
-
Pogacar faces defiant Evenepoel at Liege-Bastogne-Liege
-
Chelsea eye great escape against Barcelona in Women's Champions League
-
Iran, US to hold new round of high-level nuclear talks
-
'Energy and effort' pay off for Reds as Blues' woes continue
-
Albatross and closing birdie lift China's Liu to LPGA Chevron lead
-
On the horizon? Wave of momentum for high seas treaty
-
Top Mistakes to Avoid When Building Credit History
-
Developing countries should fast-track US trade deals: World Bank president
-
Grizzlies' Morant 'doubtful' for must-win game 4 v Thunder
-
Trump in Rome for pope funeral in first foreign trip of new term
-
Trump says Russia-Ukraine deal 'very close' after new Kremlin talks
-
US rookies lead PGA pairs event with McIlroy and Lowry in hunt
-
Trump tariff promises get a reality check
-
Warriors coach Kerr 'relatively optimistic' injured Butler will play game 3
-
Postecoglou hopes 'Stonecutter's Credo' can inspire Spurs
-
PSG lose unbeaten Ligue 1 record ahead of Arsenal showdown
-
Venezuela accuses El Salvador president of 'human trafficking'
-
Own goal takes Sundowns to African final against Pyramids
-
Scores of buildings damaged, 20 injured in Ecuador quake
-
US stocks extend rally as market eyes busy calendar next week
-
Pope's death triggers surge of disinformation he fought against
-
Rovanpera takes control of Rally Islas Canarias
-
Zelensky insists Crimea is Ukrainian as US envoy meets Putin
-
Patel and Mendis help Sunrisers beat Kings in Dhoni's 400th T20
-
Copa del Rey ref statements 'unacceptable': Real Madrid after boycotting final build-up
-
Insurance CEO's accused killer pleads not guilty to federal murder charges
-
FBI arrests Wisconsin judge for shielding undocumented migrant
-
Brazil ex-president Collor de Mello jailed for corruption
-
Zelensky insists Crimea 'belongs' to Ukraine as US envoy meets Putin
-
Real Madrid boycott Copa del Rey build-up over referee complaints
-
Trinidad and Tobago votes for parliament, PM, with opposition in lead
-
IMF chief hails 'constructive' Spring Meetings held under tariff uncertainty
-
Iran FM Araghchi in Oman ahead of nuclear talks with US
-
Dozens of buildings destroyed, 20 injured in Ecuador quake
-
Young Barca must 'enjoy' Real Madrid Copa final fight: Flick
-
Pakistan and India border closure separates families
-
Brazil's Bolsonaro 'stable' after post-surgery setback
-
Catholics in secular Cuba hail Francis as 'bridge'
-
US envoy Witkoff, Putin discuss 'possibility' of direct Russia-Ukraine talks
-
Community seeks answers after French school knife killing

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.
The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions.
Strategic Investors and Placement Details
The financing was led by Gravitas Capital and SDS Capital Group, alongside other biotechnology-focused private investors. President Street Global served as the exclusive placement agent for the offering, ensuring seamless execution of the transaction.
After deducting placement agent fees and other offering-related expenses, the Company intends to allocate the net proceeds toward clinical development, including advancing its flagship TH104 development program, as well as general working capital.
Advancing Innovation in Biotechnology
This financing reinforces Tharimmune's commitment to advancing its portfolio of therapeutic candidates. TH104, the Company's lead clinical asset, is designed to address chronic pruritus associated with primary biliary cholangitis (PBC), a rare and challenging autoimmune liver disease.
Regulatory Details
The securities in this private placement were offered under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D thereunder. The shares of common stock and underlying warrants are not registered under the Securities Act or state securities laws. The Company has agreed to file a resale registration statement covering these securities to enable their future trading upon registration or qualification under applicable laws.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies in immunology, inflammation, and oncology. The Company's lead product candidate, TH104, leverages a unique transdermal buccal film technology designed to address inflammatory conditions, including pruritus associated with PBC. Tharimmune is also advancing TH023, an oral TNF-alpha inhibitor, and exploring novel multi-specific biologics targeting solid tumors. Through a licensing agreement with OmniAb, Inc., the Company harnesses cutting-edge antibody discovery platforms to target specified disease markers. Learn more at www.tharimmune.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
Contact Information
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
SOURCE: Tharimmune, Inc.
S.F.Warren--AMWN